Analyzing GlucoTrack (NASDAQ:GCTK) & Accuray (NASDAQ:ARAY)

GlucoTrack (NASDAQ:GCTK) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 64.1% of Accuray shares are owned by institutional investors. 46.5% of GlucoTrack shares are owned by company insiders. Comparatively, 4.2% of Accuray shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares GlucoTrack and Accuray”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$7.10 million	($2.83)	-0.06
Accuray	$444.20 million	0.50	-$15.55 million	($0.17)	-12.88

GlucoTrack has higher earnings, but lower revenue than Accuray. Accuray is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for GlucoTrack and Accuray, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	0	0	0	0	0.00
Accuray	0	0	2	0	3.00

Accuray has a consensus target price of $9.00, suggesting a potential upside of 310.96%. Given Accuray’s stronger consensus rating and higher possible upside, analysts plainly believe Accuray is more favorable than GlucoTrack.

Profitability

This table compares GlucoTrack and Accuray’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-826.43%	-707.26%
Accuray	-3.72%	-36.93%	-3.52%

Risk & Volatility

GlucoTrack has a beta of -0.28, suggesting that its stock price is 128% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.

Summary

Accuray beats GlucoTrack on 9 of the 13 factors compared between the two stocks.

About GlucoTrack

GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.